WO2013162484A1 - A combination of fig (ficus carica) fruit extract and olive (olea europaea) leaf extract - Google Patents

A combination of fig (ficus carica) fruit extract and olive (olea europaea) leaf extract Download PDF

Info

Publication number
WO2013162484A1
WO2013162484A1 PCT/TR2012/000157 TR2012000157W WO2013162484A1 WO 2013162484 A1 WO2013162484 A1 WO 2013162484A1 TR 2012000157 W TR2012000157 W TR 2012000157W WO 2013162484 A1 WO2013162484 A1 WO 2013162484A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
olive
extract
pharmaceutical combination
used
combination
Prior art date
Application number
PCT/TR2012/000157
Other languages
French (fr)
Inventor
Mustafa ERASLAN
Mustafa TEKIN
Original Assignee
Eraslan Mustafa
Tekin Mustafa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/60Moraceae (Mulberry family), e.g. breadfruit or fig
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/63Oleaceae (Olive family), e.g. jasmine, lilac or ash tree

Abstract

The present invention is related to a pharmaceutical product produced from the defined sections of figs (Ficus carica) and olives (Olea europaea), in order to be used as a supplement and supportive in eliminating formed cancer cells and in preventing the formation of cancer cells, and the formulation of said product.

Description

DESCRIPTION

A COMBINATION OF FIG {Ficus carica) FRUIT EXTRACT AND OLIVE {Olea europaea) LEAF EXTRACT The present invention is related to a pharmaceutical product produced from the defined sections of figs {Ficus carica) and olives {Olea europaea), in order to be used as a supplement and supportive in eliminating formed cancer cells and in preventing the formation of cancer cells, and the formulation of said product. Ficus carica (fig) from the Moracae family inside the combination developed, has many wild and cultural sub types. The nutritional value of this fruit is high. Inside its compound, invert sugar (Sacarose mixtures such as Fructose, Glycose etc), pectine, fixed oils and protein is present. It contains vitamins B,C, and D and Provitamin A (β- Carotene), iron, potassium, phosphor, sulphur, magnesium, calcium and sodium. Fig, prevents the spreading and growth of cancerous cells via the anthocyanydol, flavanoid and polysaccharites it contains. Figs strengthen the immune system of the body against cancer, gives energy to the body and helps in eliminating exhaustion and fatigue. It repairs and renews cells with the protein it contains. It also boosts blood with its rich iron mineral content. Some benefits of figs are that they contain high amount of fibre, thus relieving your bowels, they speed up your digestive system, they are good in treating constipation and have a laxative effect. Figs can also be used in treating hemorroids. Figs have a protective effect against many cancer types. As it is beneficial in treating especially discomforts in the digestive system it is indicated that figs can prevent colon cancer.

One of the benefits of figs is that they have an effect to lower cholesterol by balancing the fat rates in blood. By balancing the fat rate cardiovascular diseases are also prevented. When cholesterol increase is prevented, the accumulation of cholesterol in kidneys is also prevented thus ensuring that kidney failure diseases are eliminated. Another benefit of figs is that it also balances blood sugar. Figs contain a high amount of fibres which help in weight loss. Olive tree leaves within the developed combination are acquired from olive (Olea europaea) trees which is a tree specific to the Meditteranean climate whose fruit originates from the olive (Oleaceae) family.

Olives contain a high amount of vegetal protein, oils, A, C, E vitamins, and minerals such as calcium, phosphor, sulphur, chlorine, and magnesium. Olives are very beneficial for obtaining cardiovascular health and they also decrease the effects of aging. It is known by the American Canser Research Institute that olive leaves are the 21 'st Century's most effective natural antimicrobial and antiviral plants. There are 69 books, more than 800 articles, journals and various other publications regarding this issue. Besides the effects of olive leaves in relation to the balancing of the blood sugar levels and its effects as an antimicrobial, antiviral and antioxidant agent it is also known that olive leaves effect the coronary veins and helps to increase LDL cholesterol levels. Olive leaves are also effective in curing other diseases and microorganisms such as bronchitis, common cold, ear infections, Epstein bar virus, fibromalaria, fungal infections, herpes virus, Chlamydia sp., dysentery, streptococcus sp., hepatitis A, B, C, pneumonia, skin diseased, shingles and rheumatismal diseases.

Oleuropein is a phytochemical that can be found in abundance in olive trees. Oleuropein and hydroxytyrosol which is a degradation product, are both very effective antioxidants. Oleuropein are known to have pharmacological effects that can strengthen the immune system, and balance blood pressur and blood sugar. Oleuropein, is found in the barks of olive trees, its trunk, fruits, oil and mostly in the leaves of olive trees (40 times more in comparison to the amount found in olive oil). Oleuropein is the primary molecule that shows antioxidant characteristics in olive tree leaves. In the laboratory studies carried out, it has been observed that oleuropein prevented (antioxidant effect) the oxidization of LDL cholesterol. The extracts (essence) of olive tree leaves are very beneficial to the health and do not have any toxic characteristics. Dry olive tree leave extracts which comprises 6-15% of oleuropein are being commercially traded.

The natural antioxidants inside the olive tree leaves are as follows: Phenolic compounds such as oleuropein, hrydoxytyrosol, verbascosyte, Apigenin-7-glucosate, Luteolin-7-glucosate, Tyrosole, Vanillic acid, Diosmetin-7-glucosate, Cafeic acid, Luteolin, Rutin, Diosmetin, Vanillin, catechin.

In the Chinese patent application numbered CN101375700 a production method of the dried fruit of Ficus carica in order to increase the strength of the immune system against cancer is described. In the Chinese patent application numbered CN101375695 a production method of the dried fruit of Ficus carica to be used against cancer and cardiovascular diseases is described.

In the Chinese patent application numbered CN 1814153 describes a formulation of Ficus Carica, mixed with herbal products such as Radix Astragali, Chinese Angelica, Radix Asparagi, Fructus Aurantii Immaturus used in preventing breast cancer.

In the German patent application numbered DEI 02009038565 the usage of olive tree leave extracts, together with some extracts such as, apple juice extracts, wine and kiwi seed extracts to provide cytostatic, anti- inflammatory and immunostimulant effects is described.

In the Chinese patent application numbered CN101095447 the usage of Ficus carica, prepared with a combination of olives, mushrooms, onions, honeysuckle flowers as a coffee in order to treat in getting rid of toxins and to be used in beauty treatment is described. The effects such as strengthening the immune system, and antioxidant effects of both ficus carica fruit (fig) extract and olive leaf extracts which are included in the present combination have been known for many years.

With the present combination which has been developed the effects such as strengthening the immune system and antioxidant effects of figs and olive leaves have been improved. The present invention has ensured that instead of using both products separately, the extracts of the two ingredients were combined thus providing an increase in bio-availability.

If olive leaves, and figs or extracts thereof were to be taken separately, most of the active agents inside these could be excreted out of the body being met by intestinal bacteria before being absorbed or before breaking down in the stomach and changing into compounds that the body could benefit from.

In the combination developed according to the present invention, as a result of using the fig fruit extract and the olive leaf extract together a synergy is achieved and the necessary theraupetic dose is acquired. Preparation method (Cyrup):

Sweeteners and preservatives are added inside a sufficient amount of water and the water is heated and then cooled. As a sweetener all kinds of sweeteners and artificial sweeteners can be used. On top of this fig fruit extract and olive leaf extract is added and mixed. Propylenglycole and glycerol is added to the mixture as a stabilizer and the mixture is mixed further. Citric acid is prepared between pH 5-6. All kinds of tampon material that can balance Ph instead of citric acid can be used and pure water is added to achieve the complete volume that is desired. The mixture is mixed for a while, then poured into 100 or 200ml glass bottles.

Preparation method (solid gelatine capsule):

In this combination taken orally developed for solid and liquid forms, the solid fig fruit extract and the solid olive leaf extracts are taken in different proportions, magnesium stearate is added and the mixture is mixed until a homogenous mixture is obtained. Other lubricants can be used instead of magnesium stearate.

The homogenous mixture is filled into gelatine capsules. The combination can be produced in all kinds of hard, liquid and semi liquid dosage forms, presented as soft gelatine capsules, as tablets, pellets, sachets and cyrup.

The olive leaf extract amount and the fig fruit extract amounts added into the mixture can vary according to the amouns of active ingredients they comprise. For this reason each extract amount may be different inside a combination. Against 1 unit of fig fruit extract within the combination 1 to 5 units of oleuropein carrying extract of the olive leave could be present. Liquid extracts can be used within the combination and so can solid extracts.

The extract combination developed according to the present invention can be used as a supportive or supplemental product in preventing the formation of cancerous cells, eliminating formed cancer cells, strengthening the immune system, regulating blood pressure and blood sugar.

Claims

1. An herbal pharmaceutical combination prepared with a mixture of extracts obtained from the defined sections of figs (Ficus carica) and olives (Olea europaea).
2. An herbal pharmaceutical combination according to Claim 1, wherein the fruit extract of figs are used.
3. An herbal pharmaceutical combination wherein the leaf extract of the olives mentioned in Claim 1 are used.
4. An herbal pharmaceutical combination according to Claim 1, 2 and 3, wherein the olive leaf extract rate is 1 to 5 units against the 1 unit of fig fruit extract.
5. An herbal pharmaceutical combination according to Claim 4, wherein the combination comprises preferably 3 units of olive leaf extract against the 1 unit of fig fruit extract.
6. An herbal pharmaceutical combination according to claims 1, 2, 3, 4 and 5 wherein said mixture indicated to be used as a supportive or supplemental product in preventing the formation of cancerous cells, eliminating formed cancer cells, strengthening the immune system, regulating blood pressure and blood sugar.
PCT/TR2012/000157 2012-04-24 2012-09-28 A combination of fig (ficus carica) fruit extract and olive (olea europaea) leaf extract WO2013162484A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2012/04750 2012-04-24
TR201204750 2012-04-24

Publications (1)

Publication Number Publication Date
WO2013162484A1 true true WO2013162484A1 (en) 2013-10-31

Family

ID=47902332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2012/000157 WO2013162484A1 (en) 2012-04-24 2012-09-28 A combination of fig (ficus carica) fruit extract and olive (olea europaea) leaf extract

Country Status (1)

Country Link
WO (1) WO2013162484A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3216869A1 (en) 2016-03-09 2017-09-13 Colizzi, Vittorio Nutraceutical plant derived microrna elements for treatment of cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534364A (en) 1983-09-19 1985-08-13 Lamoreux Larry W Sagittal knee test apparatus
WO1988004536A1 (en) 1986-12-19 1988-06-30 Lusuardi, Werther, G. Non-invasive quantitative knee joint in vivo instability analyzer
CN101095447A (en) * 2007-07-30 2008-01-02 邵建国;孔 民;王爱民 Health-care coffee having waste-discharging and youth-keeping function and the preparing method thereof
WO2008040790A1 (en) 2006-10-05 2008-04-10 Genourob Method for detecting and monitoring injuries of the knee anterior cruciate ligament
JP2009108025A (en) * 2008-06-19 2009-05-21 Tsujido Kagaku Kk Therapeutic agent
CN102309738A (en) * 2010-07-09 2012-01-11 居华 Throat-clearing and pharyngitis-treating buccal tablet

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534364A (en) 1983-09-19 1985-08-13 Lamoreux Larry W Sagittal knee test apparatus
WO1988004536A1 (en) 1986-12-19 1988-06-30 Lusuardi, Werther, G. Non-invasive quantitative knee joint in vivo instability analyzer
WO2008040790A1 (en) 2006-10-05 2008-04-10 Genourob Method for detecting and monitoring injuries of the knee anterior cruciate ligament
CN101095447A (en) * 2007-07-30 2008-01-02 邵建国;孔 民;王爱民 Health-care coffee having waste-discharging and youth-keeping function and the preparing method thereof
JP2009108025A (en) * 2008-06-19 2009-05-21 Tsujido Kagaku Kk Therapeutic agent
CN102309738A (en) * 2010-07-09 2012-01-11 居华 Throat-clearing and pharyngitis-treating buccal tablet

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200845, Derwent World Patents Index; AN 2008-H03822, XP002695581 *
DATABASE WPI Week 200936, Derwent World Patents Index; AN 2009-J39945, XP002695583 *
DATABASE WPI Week 201225, Derwent World Patents Index; AN 2012-B46934, XP002695582 *
EDDOUKS M ET AL: "The use of medicinal plants in the treatment of diabetes in Morocco", PHYTOTHÉRAPIE, SPRINGER-VERLAG, PARIS, FR, vol. 5, no. 4, 1 October 2007 (2007-10-01), pages 194 - 203, XP009165470, ISSN: 1624-8597 *
MARRELLI M ET AL: "Changes in the phenolic and lipophilic composition, in the enzyme inhibition and antiproliferative activity of Ficus carica L. cultivar Dottato fruits during maturation", FOOD AND CHEMICAL TOXICOLOGY 2012 ELSEVIER LTD GBR, vol. 50, no. 3-4, March 2012 (2012-03-01), pages 726 - 733, XP009168865, ISSN: 0278-6915 *
RIDA FARES ET AL.: "The Antioxidant and Anti-proliferative Activity of the Lebanese Olea europaea Extract", PLANT FOODS FOR HUMAN NUTRITION (DORDRECHT), vol. 66, no. 1, March 2011 (2011-03-01), pages 58 - 63, XP009168866, DOI: 10.1007/S11130-011-0213-9 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3216869A1 (en) 2016-03-09 2017-09-13 Colizzi, Vittorio Nutraceutical plant derived microrna elements for treatment of cancer

Similar Documents

Publication Publication Date Title
Boudreau et al. An evaluation of the biological and toxicological properties of Aloe barbadensis (miller), Aloe vera
Eteraf-Oskouei et al. Traditional and modern uses of natural honey in human diseases: a review
González-Molina et al. Natural bioactive compounds of Citrus limon for food and health
Baliga et al. A review of the chemistry and pharmacology of the date fruits (Phoenix dactylifera L.)
US6605296B1 (en) Natural substances based agent
US20050266018A1 (en) Nutraceutical compositions with mangosteen
Abad et al. Baccharis (Compositae): a review update
US20080038367A1 (en) Nutritional supplement compositions and methods of preparing
Mahmood et al. Moringa oleifera: a natural gift-A review
Madrigal-Santillán et al. Review of natural products with hepatoprotective effects
Shikov et al. Medicinal plants of the Russian Pharmacopoeia; their history and applications
Ahlawat et al. Processing, food applications and safety of aloe vera products: a review
Suryakumar et al. Medicinal and therapeutic potential of Sea buckthorn (Hippophae rhamnoides L.)
Masibo et al. Mango bioactive compounds and related nutraceutical properties—A review
Street et al. Commercially important medicinal plants of South Africa: a review
Gopalan et al. The health benefits of blackcurrants
Yogiraj et al. Carica papaya Linn: an overview
Singh et al. Therapeutic potential of organic Triticum aestivum linn.(wheat grass) in prevention and treatment of chronic diseases: An overview
Kamatou et al. An updated review of Adansonia digitata: A commercially important African tree
Denisow et al. Biological and therapeutic properties of bee pollen: a review
US20030077336A1 (en) Anti-inflammatory complex containing flaxseed oil
Christaki et al. Aloe vera: a plant for many uses
Burlando et al. Herbal principles in cosmetics: Properties and mechanisms of action
Prajapati et al. Phytochemical and pharmacological review of Lagenaria sicereria
Sandhu et al. Equisetum arvense: pharmacology and phytochemistry–a review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12832785

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase in:

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 31/03/2015)

122 Ep: pct application non-entry in european phase

Ref document number: 12832785

Country of ref document: EP

Kind code of ref document: A1